ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2832

The Effect of Co-Medication with Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs on TNF Inhibitor Drug Survival in Patients with Ankylosing Spondylitis: Results from a Nationwide Prospective Study

Elisabeth Lie1,2, Lars Erik Kristensen3, Helena Forsblad-d'Elia1, Johan Askling4 and Lennart T. Jacobsson1, 1Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, 2Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3Section of Rheumatology, Department of Clinical Sciences, Lund University, Malmö, Sweden, 4Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), anti-TNF therapy and registries, DMARDs

  • Tweet
  • Email
  • Print
Session Information

Session Title: Spondyloarthropathies and Psoriatic Arthritis IV - Clinical Aspects Axial Spondyloarthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose

For rheumatoid arthritis it is well established that co-medication (co-med) with methotrexate (MTX) increases the efficacy and drug survival of TNF inhibitors (TNFi), while there has been little evidence of such a beneficial effect of co-med for ankylosing spondylitis (AS). The purpose of this study was to assess the effect of co-med with conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) on retention to TNFi therapy in AS.

Methods

Data on patients (pts) with AS starting adalimumab (ADA), etanercept (ETN) or infliximab (IFX) as their first TNFi from Jan 2003 through Dec 2010 were extracted from the Swedish Biologics Register ARTIS, including use of csDMARD co-med at baseline. Follow-up data through Dec 2011 were available at the time of analysis. Additional covariate data were obtained by linkage to the National Patient Register and Statistics Sweden. We analysed 5-year drug survival by multivariable Cox regression, including covariates that were selected a priori (Table). Additional potential confounders (ESR, CRP, patient global, 28-swollen joint count (SJC), and history of uveitis, psoriasis and inflammatory bowel disease) were also tested in the model.

Results

1365 pts with AS were included (605 IFX, 406 ADA, 354 ETN). At baseline 557 pts (40.8%) used csDMARD co-med (429 used MTX), and co-med was more often given with IFX (55.4%) than with ADA (28.1%) or ETN (30.5%). Patients on co-med had higher levels of ESR and CRP and more often ≥1 swollen joint at baseline, and remained on therapy longer vs. pts on TNFi monotherapy. Estimated median survival time (based on Kaplan-Meier of overall drug survival) was 6.0 vs. 4.2 years (log rank test p<0.001). By separate analyses per drug (Kaplan-Meier with log rank test), statistically significantly better survival rates in pts on co-med were observed for IFX (p=0.015), ADA (p=0.015) and ETN (p=0.020). The multivariable Cox regression model is shown in the Table. The hazard ratio (HR) for TNFi discontinuation for pts on csDMARD co-med was 0.71 vs. those not on co-med. We also found statistically significant associations between drug survival and ESR, CRP, patient global, 28-SJC and uveitis, respectively, while the association with csDMARD co-med remained highly statistically significant (p<0.001) with a HR of 0.58-0.70 in the models with additional adjustments (data not shown). We also tested csDMARD co-med as MTX vs. other csDMARDs vs. no csDMARD in the model shown in the Table: MTX vs. no csDMARD HR (95% CI) 0.74 (0.61-0.91) (p=0.004), and other csDMARDs vs. no csDMARD 0.59 (0.41-0.83) (p=0.002).

Table. Multivariable Cox regression analysis of 5-year drug survival

HR (95% CI)

p-value

Age (per 10 years)

1.01 (0.94-1.09)

0.739

Sex (ref. female)

0.66 (0.55-0.80)

<0.001

csDMARD co-medication (ref. none)

0.71 (0.59-0.85)

<0.001

TNFi type

0.037

ADA vs. IFX

0.90 (0.73-1.11)

0.317

ETN vs. IFX

0.75 (0.60-0.93)

0.010

Start year 2007-2010 vs. 2003-2006

1.22 (1.01-1.48)

0.037

Hospital days*

1.01 (1.00-1.01)

0.008

Number of outpatient visits*

1.02 (1.00-1.03)

0.010

Disposable income (per 1000 €)†

0.99 (0.99-1.00)

0.146

Education‡

0.087

10-12 years vs. ≤9 years

0.93 (0.73-1.17)

0.532

>12 years vs. ≤9 years

0.78 (0.60-1.01)

0.060

Missing vs.. ≤9 years

2.55 (0.62-10.4)

0.192

*Number of days/visits the 2 years prior to TNFi start; data from the National Patient Register

†Income the year prior to TNFi start; data from Statistics Sweden

‡Data from Statistics Sweden

Conclusion

AS patients who received csDMARD co-med with their first TNFi remained on therapy significantly longer than those who were not on co-med. The association remained statistically significant when adjusting for potential confounders.


Disclosure:

E. Lie,

AbbVie,

5,

UCB,

5,

Bristol-Myers Squibb,

5,

Hospira,

5,

Pfizer Inc,

5,

AbbVie,

8,

UCB,

8;

L. E. Kristensen,

Pfizer Inc,

5,

UCB,

5,

AbbVie,

5,

MSD,

5,

Pfizer Inc,

8,

UCB,

8,

AbbVie,

8,

MSD,

8;

H. Forsblad-d’Elia,
None;

J. Askling,

AstraZeneca; Pfizer;,

2;

L. T. Jacobsson,

Pfizer Inc,

5,

AbbVie,

5,

UCB,

5.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-effect-of-co-medication-with-conventional-synthetic-disease-modifying-anti-rheumatic-drugs-on-tnf-inhibitor-drug-survival-in-patients-with-ankylosing-spondylitis-results-from-a-nationwide-prospec/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies